CClinicalTrials.gg
Status unknownNCT05650684PoursuitAllaitUpdated Dec 16, 2022

Factors Associated With Continuation of Exclusive Breastfeeding Until the Post-natal Visit

An observational study in Breastfeeding, sponsored by Université de Reims Champagne-Ardenne. Status unknown. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-16.

Sponsored by Université de Reims Champagne-Ardenne · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Study summary

Breastfeeding promotes the health of mother and her child, and remains the reference in terms of infant nutrition. World Health Organization recommends exclusive breastfeeding for the first six months. This recommended duration is not respected in France with a median duration of breastfeeding in France at 3 months.

Read the detailed description

The aim is to study factors associated with continuation of exclusive breastfeeding until the post-natal visit.

02

Conditions studied

  • Breastfeeding

Keywords

  • exclusive breastfeeding
  • postnatal visit
  • factors associated
03

In context

Lead sponsor

Université de Reims Champagne-Ardenne is the lead sponsor of 62 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Mother initiating exclusive breastfeeding after birth

Inclusion criteria

  • primiparous and multiparous women
  • women who have initiate breastfeeding
  • women aged 18 and more
  • agreeing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • women whose newborn has been in intensive care unit
  • women with a multiple pregnancy
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • "exclusive breastfeeding" group

    Women initiating exclusive breastfeeding after birth

    Other: data collection

Interventions

  • Otherdata collection

    continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)

06

What researchers measure

Primary outcomes

  1. breastfeeding

    number of women practicing or not exclusive breastfeeding until postnatal consultation (6 to 8 weeks after birth)

    Time frame: Day 0

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05650684
Lead sponsor
Université de Reims Champagne-Ardenne
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
Apr 1, 2023 (estimated)
Completion
Jul 1, 2023 (estimated)
Last update
Dec 16, 2022

Study contacts

CURRS CURRS
Contact
currs@univ-reims.fr
0326918822

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion